Cullinan Therapeutics, Inc. (CGEM) — Cash & Equivalents
| Fiscal Year | Cash & Equivalents | Change YoY |
|---|---|---|
| 2025 | $88.33M | +6.4% |
| 2024 | $83.00M | -15.7% |
| 2023 | $98.43M | -37.0% |
| 2022 | $156.15M | +161.2% |
| 2021 | $59.77M | -64.5% |
| 2020 | $168.20M | — |
| Fiscal Year | Cash & Equivalents | Change YoY |
|---|---|---|
| 2025 | $88.33M | +6.4% |
| 2024 | $83.00M | -15.7% |
| 2023 | $98.43M | -37.0% |
| 2022 | $156.15M | +161.2% |
| 2021 | $59.77M | -64.5% |
| 2020 | $168.20M | — |